Status:
COMPLETED
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
Lead Sponsor:
Chugai Pharmaceutical
Conditions:
Chemotherapy Induced Anemia
Eligibility:
All Genders
20-79 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the effectiveness and safety of recombinant human erythropoietin in anemic cancer patients undergoing chemotherapy.
Eligibility Criteria
Inclusion
- Cancer patients
Exclusion
- a history of myocardial, cerebral or pulmonary infarction
- severe hypertension beyond control by drugs
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2005
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT00144495
Start Date
February 1 2004
End Date
May 1 2005
Last Update
February 2 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.